Literature DB >> 22459229

Glucose-6-phosphate dehydrogenase deficiency and borderline deficiency: association with neonatal hyperbilirubinemia.

Arieh Riskin1, Neta Gery, Amir Kugelman, Miri Hemo, Irina Spevak, David Bader.   

Abstract

OBJECTIVE: To characterize the occurrence of glucose-6-phosphate dehydrogenase (G6PD) deficiency and its association with neonatal hyperbilirubinemia. STUDY
DESIGN: This study involved an evaluation of G6PD data for 2656 newborns from a universal newborn screening program.
RESULTS: Mean G6PD activity was 14.2 ± 3.3 U/g Hb. Some 2.71% of the newborns were G6PD-deficient, and 1.77% had borderline G6PD activity, with male and female predominance, respectively. G6PD deficiency was more prevalent in newborns of Sephardic Jew and Muslim Arab backgrounds. The infants with G6PD deficiency had higher bilirubin levels at the time of discharge from the nursery. Infants with low and borderline G6PD activity were more likely to require phototherapy (22.2% and 25.5%, respectively, vs 7.6% of infants with normal G6PD activity; P < .005) and to have more referrals for exacerbation of jaundice (15.3% and 14.9%, respectively, vs 6.1%; P < .005). Mean G6PD activity was higher in preterm infants born at 27-34 weeks gestational age compared with those born later (16.3 ± 1.8 U/g Hb vs 14.8 ± 2.0 U/g Hb). Based on sex distribution and theoretical genetic calculations for the rate of heterozygous females, we propose that the range of borderline G6PD activity should be 2-10 U/g Hb rather than the currently accepted range of 2-7 U/g Hb.
CONCLUSIONS: There is association between G6PD deficiency and significant neonatal hyperbilirubinemia. Increased risk is also associated with borderline G6PD activity. The suggested new range for borderline G6PD activity should enhance the identification of females at risk. G6PD activity is higher in preterm infants.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22459229     DOI: 10.1016/j.jpeds.2012.02.018

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.

Authors:  M V Relling; E M McDonagh; T Chang; K E Caudle; H L McLeod; C E Haidar; T Klein; L Luzzatto
Journal:  Clin Pharmacol Ther       Date:  2014-05-02       Impact factor: 6.875

Review 2.  Parental education and the WHO neonatal G-6-PD screening program: a quarter century later.

Authors:  M Kaplan; C Hammerman; V K Bhutani
Journal:  J Perinatol       Date:  2015-07-16       Impact factor: 2.521

3.  Pediatric Provider Insight Into Newborn Screening for Glucose-6-Phosphate Dehydrogenase Deficiency.

Authors:  Janine Bernardo; Mary Nock
Journal:  Clin Pediatr (Phila)       Date:  2014-11-10       Impact factor: 1.168

4.  A model of glucose-6-phosphate dehydrogenase deficiency in the zebrafish.

Authors:  Xiaobai Patrinostro; Michelle L Carter; Ashley C Kramer; Troy C Lund
Journal:  Exp Hematol       Date:  2013-04-16       Impact factor: 3.084

5.  PCR-based allelic discrimination for glucose-6-phosphate dehydrogenase (G6PD) deficiency in Ugandan umbilical cord blood.

Authors:  Jennifer Hsu; Deanna Fink; Erica Langer; Michelle L Carter; Derrik Bengo; Susan Ndidde; Tina Slusher; Julie A Ross; Troy C Lund
Journal:  Pediatr Hematol Oncol       Date:  2013-12-05       Impact factor: 1.969

Review 6.  Dosage Compensation in Females with X-Linked Metabolic Disorders.

Authors:  Patrycja Juchniewicz; Ewa Piotrowska; Anna Kloska; Magdalena Podlacha; Jagoda Mantej; Grzegorz Węgrzyn; Stefan Tukaj; Joanna Jakóbkiewicz-Banecka
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

7.  Lower reference limits of quantitative cord glucose-6-phosphate dehydrogenase estimated from healthy term neonates according to the Clinical and Laboratory Standards Institute guidelines: a cross sectional retrospective study.

Authors:  Sameer Yaseen Al-Abdi; Amina Suleman Alsaigh; Fahima Lugman Aldawoud; Amal Ali Al Sadiq
Journal:  BMC Pediatr       Date:  2013-09-10       Impact factor: 2.125

Review 8.  Optimizing G6PD testing for Plasmodium vivax case management and beyond: why sex, counseling, and community engagement matter.

Authors:  Cindy S Chu; Germana Bancone; Maureen Kelley; Nicole Advani; Gonzalo J Domingo; Eva M Cutiongo-de la Paz; Nicole van der Merwe; Jessica Cohen; Emily Gerth-Guyette
Journal:  Wellcome Open Res       Date:  2020-08-25

9.  Prevalence of glucose-6-phosphate dehydrogenase deficiency in neonates in Egypt.

Authors:  Soheir Abo Elella; Mahaa Tawfik; Naglaa Barseem; Wafaa Moustafa
Journal:  Ann Saudi Med       Date:  2017 Sep-Oct       Impact factor: 1.526

10.  Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities.

Authors:  Gonzalo J Domingo; Nicole Advani; Ari W Satyagraha; Carol H Sibley; Elizabeth Rowley; Michael Kalnoky; Jessica Cohen; Michael Parker; Maureen Kelley
Journal:  Int Health       Date:  2019-01-01       Impact factor: 2.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.